PRNewsWire
30 Jun 2026, 04:00 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Innovent Biologics has acquired sole commercialization rights for Eli Lilly's CDK4 & 6 inhibitor Verzenios (abemaciclib) in mainland China. — This provides Innovent with a high-value, approved asset in a major therapeutic area (breast cancer) and expands its oncology revenue streams.
+0.60Verzenios has secured full coverage for both early and advanced breast cancer indications on China's National Reimbursement Drug List (NRDL). — NRDL listing is a critical driver for volume and market penetration in the Chinese pharmaceutical market.
+0.40Eli Lilly will maintain responsibility for manufacturing, supply, and ongoing product development for Verzenios in China. — This minimizes the operational risk for Innovent while ensuring Lilly retains control over the product's lifecycle and quality.
+0.10Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
Innovent secures sole commercialization rights for Verzenios in mainland China, expanding its oncology portfolio.
Lilly enters a strategic distribution agreement to enhance patient access and market reach for Verzenios in China.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
4h ago
